Abstract
To examine the epidemiology, treatment patterns, and costs of cytomegalovirus (CMV) retinitis treatment in the post-HAART (highly active antiretroviral therapy) era, a retrospective cohort study was performed using data from US managed-care plans from 1997-2002. Cases with CMV retinitis were defined by requiring diagnosis codes for HIV (or AIDS), CMV, and retinitis and claims for anti-CMV treatment. Costs of oral, intravenous, and intraocular treatment periods were examined. The incidence of enrolled HIV or AIDS cases increased from 7 per million members in 1997 to 150 per million members in 2001. The incidence of CMV retinitis decreased from 23 per 10,000 HIV or AIDS cases in 1997 to 8 per 10,000 HIV or AIDS cases in 2001. The average duration of a CMV episode was 192 days and the average cost was 19,576 US dollars. In a multiple linear regression model adjusting for age, gender, insurance type, geographic region, HAART use, and co-existing AIDS-defining illnesses, intraocular and oral treatment periods saved 7135 and US dollars and 6866 US dollars, respectively, per treatment period compared with intravenous treatment (P < 0.05). The incidence of CMV retinitis decreased in this managed-care population during the post-HAART er...Continue Reading
References
Feb 10, 1993·JAMA : the Journal of the American Medical Association
Oct 1, 1993·American Journal of Public Health·L RosenblumB Whyte
May 1, 1996·Clinical Therapeutics·S D SullivanS E Follansbee
Jan 1, 1996·AIDS·H Schuitemaker, F Miedema
Oct 1, 1996·International Journal of STD & AIDS·L Davies, A Maynard
Mar 27, 1998·The New England Journal of Medicine·F J PalellaS D Holmberg
Mar 24, 1999·American Journal of Ophthalmology·D F MartinC A Benson
Oct 4, 1996·PharmacoEconomics·J M Graf von den SchulenburgM Stoll
Mar 8, 1998·PharmacoEconomics·R I GriffithsE P Steinberg
Apr 7, 1998·PharmacoEconomics·A DesgagnéJ LeLorier
Apr 8, 1999·The New England Journal of Medicine·D F MartinC A Robinson
Oct 28, 1999·PharmacoEconomics·A RachlisA Jones
Dec 5, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·W E CunninghamN S Wenger
Jul 24, 2001·PharmacoEconomics·T A LeeT Williamson
Apr 12, 2002·The New England Journal of Medicine·Daniel F MartinUNKNOWN Valganciclovir Study Group
Citations
May 14, 2010·Clinical Ophthalmology·Michael W Stewart
Jun 4, 2005·Clinical & Experimental Ophthalmology·Weng T Ng, Patrick Versace
Nov 19, 2005·Expert Review of Medical Devices·Margaret Chang, James P Dunn
Apr 12, 2005·Drugs·Risto S Cvetković, Keri Wellington
Mar 20, 2019·Current Ophthalmology Reports·Alexander D PortMrinali P Gupta
Jun 14, 2006·International Ophthalmology Clinics·Torsten W Wiegand, Lucy H Y Young
Nov 15, 2020·BMC Infectious Diseases·Jillian MurrayIza Ciglenecki